Commentary Open Access
Volume 3 | Issue 3 | DOI: https://doi.org/10.33696/immunology.3.099

The Potential of Combination Therapies and Patient Stratification to Improve CCR2 Inhibition Therapeutics

  • 1Department of Surgery (Urology), Cedars-Sinai Medical Center, Los Angeles, CA, USA
  • 2Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA
+ Affiliations - Affiliations

Corresponding Author

Dan Theodorescu, dan.theodorescu@cshs.org

Received Date: April 11, 2021

Accepted Date: June 14, 2021


Bladder cancer, Tumor progression, PD-1, PD-L1, Cytokines, Checkpoint inhibitors, Immunotherapy, CCL2, CCR2

Author Information X